Becker Capital Management's Top Stock Holdings Experience Minor Changes in Q3-Q4 2022

When analyzing the 13F Holdings Comparison of the investment firm Becker Capital Management Inc between Q3 and Q4 of 2022, it becomes clear that the company made some minor adjustments to its portfolio. While some changes were expected, others might come as a surprise to seasoned investors.

It's essential to note that Becker Capital Management is a long-term investor, which means it doesn't make significant changes to its portfolio from one quarter to the next. Instead, it focuses on diversification and investing in high-quality companies with sustainable competitive advantages.

Here are some of the primary changes that Becker Capital Management made to its top holdings between Q3 and Q4 of 2022:

Microsoft Corp (MSFT)

Becker Capital Management increased its stake in Microsoft Corp by 3.8%, with Q4 holdings totaling 397,777 shares. The value of the stake increased from $91.894 million to $95.394 million over the same period.

Apple Inc (AAPL)

Becker Capital Management reduced its stake in Apple Inc by 5.8%, with Q4 holdings totaling 733,119 shares. The value of the stake decreased from $101.108 million to $95.254 million over the same period.

Schwab Charles Corp (SCHW)

Becker Capital Management increased its stake in Schwab Charles Corp by 17.1%, with Q4 holdings totaling 736,159 shares. The value of the stake increased from $52.344 million to $61.292 million over the same period.

JPMorgan Chase & Co (JPM)

Becker Capital Management increased its stake in JPMorgan Chase & Co by 29.6%, with Q4 holdings totaling 408,835 shares. The value of the stake increased from $42.298 million to $54.824 million over the same period.

Johnson & Johnson (JNJ)

Becker Capital Management increased its stake in Johnson & Johnson by 8.4%, with Q4 holdings totaling 255,770 shares. The value of the stake increased from $41.682 million to $45.181 million over the same period.

Pfizer Inc (PFE)

Becker Capital Management increased its stake in Pfizer Inc by 17.7%, with Q4 holdings totaling 848,407 shares. The value of the stake increased from $36.937 million to $43.472 million over the same period.

Chevron Corp New (CVX)

Becker Capital Management reduced its stake in Chevron Corp New by 24.2%, with Q4 holdings totaling 241,190 shares. The value of the stake increased from $34.851 million to $43.291 million over the same period.

Cisco Sys Inc (CSCO)

Becker Capital Management increased its stake in Cisco Sys Inc by 21.4%, with Q4 holdings totaling 846,345 shares. The value of the stake increased from $33.210 million to $40.319 million over the same period.

Merck & Co Inc (MRK)

Becker Capital Management reduced its stake in Merck & Co Inc by 26.1%, with Q4 holdings totaling 361,611 shares. The value of the stake increased from $31.822 million to $40.120 million over the same period.

Blackrock Inc (BLK)

Becker Capital Management increased its stake in Blackrock Inc by 31.9%, with Q4 holdings totaling 55,561 shares. The value of the stake increased from $29.857 million to $39.372 million over the same period.

Walmart Inc (WMT)

Becker Capital Management increased its stake in Walmart Inc by 10.1%, with Q4 holdings totaling 274,843 shares. The value of the stake increased from $35.399 million to $38.969 million over the same period.

Goldman Sachs Group Inc (GS)

Becker Capital Management increased its stake in Goldman Sachs Group Inc by 18.1%, with Q4 holdings totaling 111,774 shares. The value of the stake increased from $32.490 million to $38.380 million over the same period.

The Overall Picture

Becker Capital Management's portfolio changes suggest that they are leaning towards increasing their stakes in financial and healthcare giants. However, the company hasn't been shy about taking advantage of market dips to buy undervalued stocks from leading technology companies. These strategic decisions are aimed at increasing the diversification of their portfolio while ensuring long-term sustainable returns.

Conclusion

Becker Capital Management's quarterly 13F disclosures offer us a glimpse into the company's investment strategy and moves. The recent update shows a slightly altered portfolio that is still heavily invested in financially and pharmaceutical firms. The changes should demonstrate the company's commitment to long-term investments rather than fast cash-outs, which is a welcome approach in today's unpredictable financial world.